Targeted Biologic Therapies for Severe Asthma: Opportunities and Implications for Managed Care

Gain expert insights on the utilization of targeted biologic therapies in the management of severe asthma, to improve clinical and economic outcomes.
Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C
Geoffrey C. Wall, PharmD, FCCP, BCPS
Format: Microsoft PowerPoint (.ppt)
File Size: 938 KB
Released: May 17, 2022

Acknowledgements

Provided by ProCE, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Dr Geoffrey C. Wall discusses how updated guidelines inform the selection of appropriate therapy for patients with severe asthma, from ProCE

Geoffrey C. Wall, PharmD, FCCP, BCPS Released: June 7, 2022

Dr Jamie McConaha discusses the current understanding of atopic dermatitis pathophysiology and the latest biologic therapies used for treatment, from ProCE

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES Released: June 1, 2022

Expert commentary and downloadable slides featuring guidance for pharmacists on personalizing care for patients with moderate to severe AD

Sarah Lant, PharmD Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES Released: May 18, 2022

Downloadable slides featuring expert insight on obesity, including guideline recommendations and a review of available pharmacotherapy, from ProCE

Released: April 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings